UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007061
Receipt number R000008320
Scientific Title A pilot study of new covered metallic stent with large bore size for the unresectable distal biliary malignancies: Niti-S SUPREMO-12
Date of disclosure of the study information 2012/01/13
Last modified on 2016/05/26 01:51:37

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A pilot study of new covered metallic stent with large bore size for the unresectable distal biliary malignancies: Niti-S SUPREMO-12

Acronym

A pilot study of new covered metallic stent with large bore size for the unresectable distal biliary malignancies: Niti-S SUPREMO-12 (NEWCOMER 12)

Scientific Title

A pilot study of new covered metallic stent with large bore size for the unresectable distal biliary malignancies: Niti-S SUPREMO-12

Scientific Title:Acronym

A pilot study of new covered metallic stent with large bore size for the unresectable distal biliary malignancies: Niti-S SUPREMO-12 (NEWCOMER 12)

Region

Japan


Condition

Condition

unresectable distal biliary malignancy

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the patency and safety of a Niti-S SUPREMO-12 stent for unresectable distal biliary malignancy.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Phase II


Assessment

Primary outcomes

1) Stent occlusion rate and dysfunction rate
2) Stent patency duration
3) Time to dysfunction
4) Overall stent patency rate and function rate

Key secondary outcomes

1) Median survival time
2) Stent-related complication rate


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients with unresectable distal malignant biliary obstruction
2) Prognosis is expected more than 2 months.
3) Written informed consent is obtained.
4) Performance status is grade 2 or smaller

Key exclusion criteria

1) Patients with massive ascites
2) Patients with serious problem in any other organs
3) Patients whose stricture extends to hilar bile duct
4) Patients with Inaccessible to the duodenal papilla (ex. total gastrectomy)
5) Contraindications of endoscopic procedure
6) Patients with intestinal obstruction in the distal to the ampulla

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tsuyoshi Mukai

Organization

Gifu Municipal Hospital

Division name

Department of Gastroenterology

Zip code


Address

7-1 Kashima-cho, Gifu, Gifu, Japan

TEL

058-251-1101

Email

tsuyomukai@yahoo.co.jp


Public contact

Name of contact person

1st name
Middle name
Last name Tsuyoshi Mukai

Organization

Gifu Municipal Hospital

Division name

Department of Gastroenterology

Zip code


Address

7-1 Kashima-cho, Gifu, Gifu, Japan

TEL

058-251-1101

Homepage URL

http://mc16.medicalstream.net/cgi-bin/auth/login.cgi

Email

tsuyomukai@yahoo.co.jp


Sponsor or person

Institute

NEWCOMER12 study group

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

岐阜市民病院(岐阜県)/ Gifu Municipal Hospital (Gifu)
東京大学医学部附属病院(東京都)/ University of Tokyo Hospital (Tokyo)
岐阜大学医学部附属病院(岐阜県)/ Gifu University Hospital (Gifu)
東京医科大学(東京都)/ Tokyo Medical University (Tokyo)
北海道大学(北海道)/ Hokkaido University Graduate School of Medicine (Hokkaido)


Other administrative information

Date of disclosure of the study information

2012 Year 01 Month 13 Day


Related information

URL releasing protocol

http://gmhosp.jp/images/pdf/b9.pdf

Publication of results

Published


Result

URL related to results and publications

http://www.ncbi.nlm.nih.gov/pubmed/26927207

Number of participants that the trial has enrolled


Results

RESULTS: The technical and functional success rates of the procedures were 100%. The 6-month non-RBO rate was 50%, and the median time to RBO was 184 days. The median survival time was 241 days. Twelve patients died within 6 months after stent placement without RBO. RBO was observed in 10 patients (26%), with 7 experiencing stent occlusion and 3 experiencing stent migration. Adverse events other than RBO (at < 30 days) developed in 6 patients (16%; cholecystitis, 1; pancreatitis, 1; hyperamylasemia, 1; pancreatic ductitis, 1; abdominal pain, 2). Stent removal for reintervention was successfully completed in 8 patients.
CONCLUSIONS: Our novel FCSEMS may be safe and effective for managing malignant distal obstructions with an acceptable incidence of adverse events.

Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 11 Month 01 Day

Date of IRB


Anticipated trial start date

2012 Year 01 Month 01 Day

Last follow-up date

2013 Year 12 Month 01 Day

Date of closure to data entry

2014 Year 03 Month 31 Day

Date trial data considered complete

2014 Year 09 Month 30 Day

Date analysis concluded

2014 Year 12 Month 31 Day


Other

Other related information

A follow-up period is the time from stent placement to patient death or stent occlusion.


Management information

Registered date

2012 Year 01 Month 12 Day

Last modified on

2016 Year 05 Month 26 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000008320


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name